TIMP1 and ischemia: Protection exerted by intravenous treatment with BAY60-6583, within 24 h after ischemia, has been attributed to protection of the endothelium due to stimulation of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), to inhibition of tPA-induced matrix metalloprotease (MMP) activation, and prevention of tight junction protein degradation.